Global Breast Cancer Screening Tests Market Size Study, by Diagnostics Test Type, by End User, and Regional Forecasts 2022-2032.

Description

Global Breast Cancer Screening Tests Market was valued at approximately USD 2.93 billion in 2023 and is projected to grow with a healthy CAGR of 54.3% over the forecast period 2024-2032. Breast cancer screening tests are critical for early detection, potentially identifying the disease before symptoms manifest, which greatly improves treatment outcomes and survival rates. Key screening tools include mammography, clinical breast exams, and genetic testing, each providing unique diagnostic insights to aid in the early detection of breast cancer. Rising awareness about breast cancer, coupled with advancements in screening technology, such as digital mammography and 3D breast imaging, has bolstered the global market. Furthermore, the increasing number of government initiatives and awareness campaigns that encourage routine screening among women is a significant factor driving market growth. Programs like the Pink Ribbon campaign, as well as WHO's Global Breast Cancer Initiative, have significantly improved awareness, making breast cancer screening more accessible worldwide.

Moreover, the demand for personalized diagnostic tools, such as BRCA genetic testing, has surged due to the growing emphasis on personalized medicine. Genetic testing not only helps in identifying susceptibility to breast cancer but also enables patients and healthcare professionals to take preventive measures, thereby enhancing the scope of early detection. The reimbursement landscape has also improved globally, especially in developed regions like North America, where several healthcare plans now cover routine screening costs, further accelerating market growth.

While the market shows substantial promise, several challenges remain, such as high costs associated with advanced diagnostic tests, overdiagnosis concerns, and the limitations of traditional screening methods in patients with dense breast tissue. Nonetheless, ongoing research into new screening technologies and the integration of artificial intelligence in diagnostic tools are expected to provide significant growth opportunities for market players.

The North American region currently dominates the breast cancer screening tests market, primarily due to a well-established healthcare infrastructure, increasing awareness of early detection, and significant advancements in diagnostic technology. In contrast, the Asia-Pacific region is projected to exhibit the highest growth rate, driven by rising healthcare investments, improved accessibility to screening programs, and growing awareness initiatives in countries like China and India.

Major market players included in this report are:

General Electric Company
Myriad Genetics
Novartis
AstraZeneca
Biocrates Life Sciences AG
Pfizer
A&G Pharmaceutical, Inc.
Hologic Inc.
Siemens Healthineers
Koninklijke Philips NV
Fujifilm Holdings
Metabolomic Technologies, Inc.
Sanofi
Bayer AG
GlaxoSmithKline plc

The detailed segments and sub-segments of the market are explained below:

By Diagnostics Test Type:

Blood Marker Tests
Imaging Test
Genetic Test
Immunohistochemistry Test

By End User:

Hospitals
Diagnostic Centres
Cancer Institutes
Research Laboratories

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Breast Cancer Screening Tests Market Executive Summary

1.1. Global Breast Cancer Screening Tests Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Diagnostics Test Type
- 1.3.2. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Breast Cancer Screening Tests Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Breast Cancer Screening Tests Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Awareness and Early Detection Practices
- 3.1.2. Technological Advancements in Breast Cancer Screening
- 3.1.3. Increased Adoption of Genetic Testing
3.2. Market Challenges
- 3.2.1. False Positives and Overdiagnosis
- 3.2.2. High Cost of Advanced Screening Tests
3.3. Market Opportunities
- 3.3.1. Expansion of Breast Cancer Screening Initiatives
- 3.3.2. Technological Innovations in AI-Powered Diagnostics

Chapter 4. Global Breast Cancer Screening Tests Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Breast Cancer Screening Tests Market Size & Forecast by Diagnostics Test Type (2022-2032)

5.1. Segment Dashboard
5.2. Global Breast Cancer Screening Tests Market: Diagnostics Test Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Blood Marker Tests
- 5.2.2. Imaging Test
- 5.2.3. Genetic Test
- 5.2.4. Immunohistochemistry Test

Chapter 6. Global Breast Cancer Screening Tests Market Size & Forecast by End User (2022-2032)

6.1. Segment Dashboard
6.2. Global Breast Cancer Screening Tests Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Hospitals
- 6.2.2. Diagnostic Centres
- 6.2.3. Cancer Institutes
- 6.2.4. Research Laboratories

Chapter 7. Global Breast Cancer Screening Tests Market Size & Forecasts by Region (2022-2032)

7.1. North America Breast Cancer Screening Tests Market
- 7.1.1. U.S. Market
  - 7.1.1.1. Diagnostics Test Type Breakdown Size & Forecasts (2022-2032)
- 7.1.2. Canada Market
  - 7.1.2.1. Diagnostics Test Type Breakdown Size & Forecasts (2022-2032)
7.2. Europe Breast Cancer Screening Tests Market
- 7.2.1. U.K. Market
- 7.2.2. Germany Market
- 7.2.3. France Market
- 7.2.4. Spain Market
- 7.2.5. Italy Market
- 7.2.6. Rest of Europe Market
7.3. Asia-Pacific Breast Cancer Screening Tests Market
- 7.3.1. China Market
- 7.3.2. India Market
- 7.3.3. Japan Market
- 7.3.4. Australia Market
- 7.3.5. South Korea Market
- 7.3.6. Rest of Asia Pacific Market
7.4. Latin America Breast Cancer Screening Tests Market
- 7.4.1. Brazil Market
- 7.4.2. Mexico Market
- 7.4.3. Rest of Latin America Market
7.5. Middle East & Africa Breast Cancer Screening Tests Market
- 7.5.1. Saudi Arabia Market
- 7.5.2. South Africa Market
- 7.5.3. Rest of Middle East & Africa Market

Chapter 8. Competitive Intelligence

8.1. Key Company SWOT Analysis
8.2. Top Market Strategies
8.3. Company Profiles
- 8.3.1. General Electric Company
- 8.3.2. Myriad Genetics
- 8.3.3. Novartis
- 8.3.4. AstraZeneca
- 8.3.5. Biocrates Life Sciences AG
- 8.3.6. Pfizer
- 8.3.7. A&G Pharmaceutical, Inc.
- 8.3.8. Hologic Inc.
- 8.3.9. Siemens Healthineers
- 8.3.10. Koninklijke Philips NV
- 8.3.11. Fujifilm Holdings
- 8.3.12. Metabolomic Technologies, Inc.
- 8.3.13. Sanofi
- 8.3.14. Bayer AG
- 8.3.15. GlaxoSmithKline plc

Chapter 9. Research Process

9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
9.2. Research Attributes